Absci Announces Filing of Registration Statement for Proposed Initial Public Offering
Absci Corporation has filed a registration statement on Form S-1 with the SEC for a proposed initial public offering (IPO) of its common stock. The number of shares and price range are yet to be determined. Absci aims to list its stock on The Nasdaq Global Market under the symbol ABSI. Joint book running managers for the offering include J.P. Morgan, Credit Suisse, BofA Securities, Cowen, and Stifel. This filing does not constitute an offer to sell securities prior to registration.
- Absci is positioned to raise capital through an IPO, enhancing its financial resources for development.
- The company is utilizing its Integrated Drug Creation™ Platform for innovative biotherapeutic drug candidates.
- The absence of specified share quantity and pricing details may lead to uncertainty in potential investor interest.
- Filing for an IPO introduces regulatory scrutiny and market volatility based on market reception.
Insights
Analyzing...
VANCOUVER, Wash., June 30, 2021 /PRNewswire/ -- Absci Corporation ("Absci"), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Absci has applied to list its common stock on The Nasdaq Global Market under the symbol ABSI.
J.P. Morgan, Credit Suisse, BofA Securities, Cowen, and Stifel will act as joint book running managers for the proposed offering.
A registration statement on Form S-1 relating to the proposed offering has been publicly filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The proposed offering will be made only by means of a prospectus. Once available, a copy of the preliminary prospectus related to the offering may be obtained by contacting: J.P. Morgan Securities LLC,, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at usa.prospectus@credit-suisse.com; BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, or by e-mail at dg.prospectus_requests@bofa.com; Cowen and Company LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY,11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com.
About Absci
Absci is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. We built our Integrated Drug Creation™ Platform to accelerate discovery of novel biotherapeutic drug candidates and generation of the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to develop new protein-based drugs, including those that may be impossible to make with other technologies. Our goal is to enable the creation of better medicines by Translating Ideas into Drugs™.
View original content to download multimedia:https://www.prnewswire.com/news-releases/absci-announces-filing-of-registration-statement-for-proposed-initial-public-offering-301323624.html
SOURCE Absci
FAQ
What is the purpose of Absci's IPO filing?
When did Absci file for its IPO?
Who are the underwriters for Absci's IPO?
What is the ticker symbol for Absci on Nasdaq?
Are there any risks involved with Absci's IPO?
